Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well giving carboplatin and paclitaxel
together with cetuximab and/or cixutumumab (IMC-A12) works in treating patients with stage
IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin
and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and
cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving chemotherapy together with monoclonal antibody therapy may kill
more tumor cells. It is not yet known whether carboplatin and paclitaxel are more effective
when given with cetuximab and/or cixutumumab in treating non-small cell lung cancer.